Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection.
In a blind trial, 77 patients were randomised to receive first cadaver kidney allografts that had been perfused either with a pair of CD45 monoclonal antibodies (mAbs), in an attempt to reduce the immunogenicity of passenger leucocytes, or with control human albumin solution. No complications of mAb perfusion were observed. Patient and allograft survival were similar in both groups. Rejection episodes were recorded in 7 (18%) of the patient with mAb perfused allografts compared with 24 (63%) of the controls.
Brewer
Y
Y
Renal Unit, Dulwich Hospital, London.
Palmer
A
A
Taube
D
D
Welsh
K
K
Bewick
M
M
Bindon
C
C
Hale
G
G
Waldmann
H
H
Dische
F
F
Parsons
V
V
D000818:Animals; D000943:Antigens, Differentiation / Q000008:administration & dosage*; D003404:Creatinine / Q000097:blood; D003713:Dendritic Cells / Q000378:metabolism; D005069:Evaluation Studies as Topic; D006084:Graft Rejection / Q000187:drug effects*; D006649:Histocompatibility Antigens / Q000008:administration & dosage*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D015994:Incidence; D016030:Kidney Transplantation / Q000379:methods*; D017493:Leukocyte Common Antigens; D010477:Perfusion / Q000379:methods*; D011292:Premedication; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D014184:Transplantation, Homologous
D000943:Antigens, Differentiation; D006649:Histocompatibility Antigens; D003404:Creatinine; D017493:Leukocyte Common Antigens